“While I feel very good about the progress we’ve made in growing the deep and diverse portfolio we have in our pipeline, we do believe we need more,” Merck CEO Rob Davis said in a quarterly conference call. “We will continue to prioritize business development. Our view of deals like Prometheus, like Acceleron are still the size of deals we are very interested in if we can find great assets.”
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,